AstraZeneca Commits $100 Million To MedImmune Ventures
This article was originally published in The Pink Sheet Daily
Executive Summary
The UK-based pharma’s corporate venture arm now has $400 million under management in an evergreen fund, with an expanded global focus that includes health care information technology.
You may also be interested in...
G1 Therapeutics Gets $12.5M Series A To Advance Chemo-Protectant Agent
Based on research from the University of North Carolina and seeded by Hatteras Venture Partners, the start-up is developing cyclin-dependent kinase (CDK) 4/6 inhibitors for use in protecting the bone marrow of cancer patients receiving chemotherapy. The funding should bring the biotech through IND filing and into Phase I work.
Corporate VC Backing Influences Private M&A Step-Ups
New data show that including one or more corporate venture investors in a syndicate actually translates into a higher median step-up valuation.
Health Care Information Technology: Venture's New Darling?
As traditional venture-like returns are harder to generate from drug development and medtech plays, some frustrated VCs see new opportunities in health care information technology, an area many have traditionally avoided.